



Efficacy of Ustekinumab for the Treatment of Bio-Naïve Moderate-to-Severe Crohn's Disease Patients: Real-World Data

Inclusion Criteria

- Adult patients ≥ 18 years of age
- confirmed diagnosis of CD based on clinical and endoscopic, or radiographic data
- active clinical symptoms attributed to CD before starting UST
- Graded as moderately to severely active disease before starting UST based on endoscopic or radiographic assessment, and/or clinical assessment (graded as moderate or severe based on Harvey–Bradshaw Index score of 8–16 or >16 , respectively);
- Had at least one clinical and/or endoscopic follow-up after initiation of therapy

Exclusion Criteria

- Patients started on UST for ulcerative colitis, indeterminate colitis, pouchitis, CD of the pouch, postoperative prophylaxis for CD or previous exposure to biologic